Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

498
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
498
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

433
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
433
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

316
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
316
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

505
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
505
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

638
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
638
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

310
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
310

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Men's health in the modern era of cystic fibrosis.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2020
Same author

The effect of dry needling on gastrocnemius muscle stiffness and strength in participants with latent trigger points.

Journal of electromyography and kinesiology : official journal of the International Society of Electrophysiological Kinesiology·2020
Same author

Scimitar syndrome with bicuspid aortic valve. A case report of cross-sectional non- invasive imaging allowing a complete anatomical and functional assessment.

Annales de cardiologie et d'angeiologie·2020
Same author

A 4-year summary of the nonsurgical recovery of baboon embryos: A report on 498 eggs.

American journal of primatology·2020
Same author

Corrigendum to "WS04.1 The effect of Orkambi® on exercise capacity and muscle strength" [J Cyst Fibros, volume 16, supplement 1, June 2017, pages S6-S7].

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2017
Same author

Targeting the PI3K/Akt/mTOR signalling pathway in Cystic Fibrosis.

Scientific reports·2017

Related Experiment Video

Updated: Nov 23, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.4K

Changes in fecal microbiota with CFTR modulator therapy: A pilot study.

C E Pope1, A T Vo1, H S Hayden1

  • 1University of Washington, Seattle, USA.

Journal of Cystic Fibrosis : Official Journal of the European Cystic Fibrosis Society
|January 4, 2021
PubMed
Summary

CFTR modulator therapies showed trends toward improved gut health in cystic fibrosis patients with pancreatic insufficiency. Lumacaftor/ivacaftor treatment in PI-CF patients suggested reduced malabsorption and a healthier gut microbiome.

Keywords:
AntibioticsCFTR modulatorsDysbiosisFecal microbiome

More Related Videos

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.2K
Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

4.9K

Related Experiment Videos

Last Updated: Nov 23, 2025

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.4K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

3.2K
Murine Fecal Isolation and Microbiota Transplantation
07:32

Murine Fecal Isolation and Microbiota Transplantation

Published on: May 26, 2023

4.9K

Area of Science:

  • Gastroenterology
  • Pulmonology
  • Microbiology

Background:

  • Cystic Fibrosis (CF) with pancreatic insufficiency (PI) is linked to fecal dysbiosis.
  • Dysbiosis drivers include antibiotics, diet, and CF-related GI dysfunction like malabsorption.

Purpose of the Study:

  • To investigate if CFTR modulator therapies alter fecal malabsorption markers and microbiome composition in CF patients.
  • To assess changes in pancreatic sufficient (PS) and pancreatic insufficient (PI) CF cohorts.

Main Methods:

  • Pilot study analyzing fecal samples from CF patients initiating ivacaftor (PS cohort) or lumacaftor/ivacaftor (PI cohort).
  • Measured fecal fat content and analyzed microbiome composition.

Main Results:

  • No statistically significant changes were observed in either cohort.
  • Trends in the PI cohort showed decreased fecal fat and a microbiome shift towards that of non-PI individuals with lumacaftor/ivacaftor.

Conclusions:

  • Findings support a model where CF-induced PI and malabsorption drive fecal dysbiosis.
  • Larger studies are needed to validate these trends with highly effective CFTR modulators.